en

PRODUCT DETAIL

Apremilast Krka d.d. 10 mg filmom obalené tablety Apremilast Krka d.d. 20 mg filmom obalené tablety Apremilast Krka d.d. 30 mg filmom obalené tablety

Code 7277E
MA number 59/0205/24-S
Product Form: tbl flm 27 (4x10 mg + 4x20 mg + 19x30 mg - začiat.liečba) (blis.OPA/Al/PVC//Al)
MA Status: R - Valid Marketing Authorisation
Type of procedure: Decentralised
MAH, country: KRKA, d.d., Novo mesto, Slovenia
Therapeutic Class: 59 - IMMUNOPRAEPARATA
ATC:
L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
L04 Immunosuppressants
L04A Immunosuppressants
L04AA Selective immunosuppressants
L04AA32 Apremilast
Shelf life: 24
Container: blister OPA/Al/PVC/Al
Route of admin.: Oral use
Prescription Status: Medicinal product subject to restricted medical prescription.
Legal basis: Article 10(1) generic application
MA issued: 28.08.2024
Validity: 28.08.2029
PIL: PIL_Apremilast Krka d.d._08.2024.pdf  
SPC: SPC_Apremilast Krka d.d._08.2024.pdf  
Dokument: VHS_SK_H_0306_0307_0309_001-002_DC_Apremilast Krka d.d.Apremilast Krka Apremilast HCS_PAR.pdf  
Dokument: VHS_súhrn_SK_H_0306_0307_0309_001-002_DC_Apremilast Krka d.d.,Apremilast Krka, Apremilast HCS_Summary PAR.pdf  
Safety feature Yes
Data update: 09.09.2024
eu-flag.png sk-flag.png